Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282
- PMID: 1317151
- PMCID: PMC189231
- DOI: 10.1128/AAC.36.1.81
Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282
Abstract
A number of quinolones and related antibacterial compounds were screened for activity against calf thymus topoisomerase II by using the P4 unknotting and DNA breakage assays. Several compounds from different structural classes which inhibited DNA unknotting with 50% inhibitory concentrations ranging from 8 to 25 micrograms/ml were identified. Two experimental isothiazoloquinolones from this group, designated A-65281 and A-65282, were also found to induce considerable DNA breakage mediated by calf thymus topoisomerase II, with 32P-end-labeled pBR322 as the substrate. These compounds were nearly as potent as teniposide, with DNA breakage activity evident at concentrations as low as 4 micrograms/ml. However, some differences in DNA cleavage patterns from those with teniposide were evident. These studies have thus identified a new class of agents which have activity against both bacterial and eukaryotic type II topoisomerases. The implications of these data for the selectivity of topoisomerase-directed compounds and the potential toxicity of such compounds developed as antibacterial agents are discussed.
Similar articles
-
Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.Antimicrob Agents Chemother. 1989 Oct;33(10):1697-703. doi: 10.1128/AAC.33.10.1697. Antimicrob Agents Chemother. 1989. PMID: 2556075 Free PMC article.
-
Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.Antimicrob Agents Chemother. 1998 May;42(5):1284-7. doi: 10.1128/AAC.42.5.1284. Antimicrob Agents Chemother. 1998. PMID: 9593169 Free PMC article.
-
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.Mol Pharmacol. 1995 Aug;48(2):238-49. Mol Pharmacol. 1995. PMID: 7651357
-
Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.Curr Pharm Des. 2001 Mar;7(5):337-53. doi: 10.2174/1381612013398013. Curr Pharm Des. 2001. PMID: 11254893 Review.
-
Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.Infect Disord Drug Targets. 2007 Mar;7(1):3-9. doi: 10.2174/187152607780090748. Infect Disord Drug Targets. 2007. PMID: 17346206 Review.
Cited by
-
The future of the quinolones.Drugs. 1993;45 Suppl 3:1-7. doi: 10.2165/00003495-199300453-00003. Drugs. 1993. PMID: 7689439 Review.
-
Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.Antimicrob Agents Chemother. 1993 Apr;37(4):646-51. doi: 10.1128/AAC.37.4.646. Antimicrob Agents Chemother. 1993. PMID: 8388196 Free PMC article.
-
Quinolone mode of action--new aspects.Drugs. 1993;45 Suppl 3:8-14. doi: 10.2165/00003495-199300453-00004. Drugs. 1993. PMID: 7689456 Review.
-
Drug repurposing of fluoroquinolones as anticancer agents in 2023.RSC Adv. 2024 Nov 20;14(50):37114-37130. doi: 10.1039/d4ra03571b. eCollection 2024 Nov 19. RSC Adv. 2024. PMID: 39569131 Free PMC article. Review.
-
Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.Bioorg Med Chem. 2010 Apr 1;18(7):2756-66. doi: 10.1016/j.bmc.2010.02.013. Epub 2010 Feb 11. Bioorg Med Chem. 2010. PMID: 20206533 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources